11,286 Shares in Repligen Corporation $RGEN Bought by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP acquired 11,286 Repligen shares worth approximately $1.54 million during the second quarter. Institutional investors collectively own 97.64% of RGEN’s outstanding stock.
• Analyst sentiment remains positive, with Repligen carrying a consensus “Buy” rating and an average price target of $166.43; several firms recently upgraded the stock or raised their targets.
• Repligen exceeded quarterly expectations, reporting adjusted EPS of $0.54 versus the $0.45 consensus and revenue of $204.13 million, up 11.9% year over year. The company issued fiscal 2026 EPS guidance of $2.03 to $2.09.

Corient Private Wealth LP bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,286 shares of the biotechnology company's stock, valued at approximately $1,540,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. AQR Capital Management LLC purchased a new stake in shares of Repligen during the first quarter worth about $262,000. Jones Financial Companies Lllp raised its position in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock valued at $814,000 after purchasing an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock worth $18,067,000 after purchasing an additional 20,375 shares in the last quarter. Bank of Nova Scotia boosted its stake in Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company's stock worth $3,951,000 after purchasing an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company's stock worth $3,880,000 after purchasing an additional 7,148 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In other news, CFO Jason Garland sold 733 shares of the company's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of recent analyst reports. Citigroup upgraded shares of Repligen to a "buy" rating in a research note on Tuesday, July 7th. HSBC lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Benchmark raised Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Finally, Wolfe Research began coverage on Repligen in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $145.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Repligen currently has an average rating of "Buy" and a consensus price target of $166.43.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $169.61 on Friday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73. The company's 50 day moving average is $155.13 and its 200 day moving average is $134.02. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.57 billion, a PE ratio of 232.34, a price-to-earnings-growth ratio of 3.16 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm's revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts forecast that Repligen Corporation will post 2.06 EPS for the current year.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source